2-((3,5-二氯苯基氨基)亚甲基)丙二酸二乙酯 | 93514-78-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-((3,5-二氯苯基氨基)亚甲基)丙二酸二乙酯
• 英文名称: diethyl 2-((3,5-dichlorophenylamino)methylene)malonate
• 英文别名: Diethyl 2-[(3,5-dichloroanilino)methylene]malonate；diethyl 2-[(3,5-dichloroanilino)methylidene]propanedioate
• CAS: 93514-78-4
• 化学式: C₁₄H₁₅Cl₂NO₄
• 分子量: 332.183
• InChiKey: PZLMHLRMNPZIET-UHFFFAOYSA-N

物化性质

• 熔点：
  86.4-88.3 °C
• 沸点：
  381.6±42.0 °C(Predicted)
• 密度：
  1.335±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-((3,5-二氯苯基氨基)亚甲基)丙二酸二乙酯 在 二苯醚 、 一水合肼 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 19.0h， 生成 5,7-Dichloro-4-hydroxy-quinoline-3-carboxylic acid [1-phenyl-meth-(Z)-ylidene]-hydrazide
  参考文献：
  名称：

  Chattopadhyay; Basu, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1990, vol. 29, # 1, p. 98 - 100

  摘要：

  DOI：
• 作为产物：
  描述：

  乙氧基甲叉丙二酸二乙酯 、 3,5-二氯苯胺 反应 5.5h， 生成 2-((3,5-二氯苯基氨基)亚甲基)丙二酸二乙酯
  参考文献：
  名称：

  多步合成2-芳基-2 H-吡唑并[4,3 - c ]-喹啉-3-酮的替代方法

  摘要：

  方便地制备了一系列2-芳基-2 H-吡唑并[4，3 - c ]喹啉-3-酮衍生物6和7。从二氯苯甲烷和溴苯胺（1a – b）到2-（乙氧基亚甲基）丙二酸二乙酯，使用经过稍微修饰的Gould-Jacobs反应进行了多步合成。在这项工作中，我们提出了一种新颖的氯化策略，以高收率制备喹啉衍生物4作为目标化合物合成中的关键中间体。评价了几种反应条件以优化吡唑并喹啉酮核的形成。两种氯喹啉酮4a–b的化学行为差异 还讨论了与芳基和苄基肼形成的芳基。

  DOI：

  10.1016/j.tetlet.2009.10.123

文献信息

• An alternative approach toward 2-aryl-2H-pyrazolo[4,3-c]-quinolin-3-ones by a multistep synthesis
  作者：Marisa J. López Rivilli、Elizabeth L. Moyano、Gloria I. Yranzo

  DOI：10.1016/j.tetlet.2009.10.123

  日期：2010.1

  carried out starting from dichloro- and bromoanilines (1a–b) and diethyl 2-(ethoxymethylene)malonate using a slightly modified Gould-Jacobs reaction. In this work we present a novel chlorination strategy to prepare quinoline derivatives 4 in excellent yields as key intermediates in the synthesis of the target compounds. Several reaction conditions were evaluated to optimize the formation of pyrazoloquinolinone

  方便地制备了一系列2-芳基-2 H-吡唑并[4，3 - c ]喹啉-3-酮衍生物6和7。从二氯苯甲烷和溴苯胺（1a – b）到2-（乙氧基亚甲基）丙二酸二乙酯，使用经过稍微修饰的Gould-Jacobs反应进行了多步合成。在这项工作中，我们提出了一种新颖的氯化策略，以高收率制备喹啉衍生物4作为目标化合物合成中的关键中间体。评价了几种反应条件以优化吡唑并喹啉酮核的形成。两种氯喹啉酮4a–b的化学行为差异 还讨论了与芳基和苄基肼形成的芳基。
• Synthesis and biological evaluation of novel 3-(quinolin-4-ylamino)benzenesulfonamides as carbonic anhydrase isoforms I and II inhibitors
  作者：Mohammad M. Al-Sanea、Ahmed Elkamhawy、Sora Paik、Silvia Bua、So Ha Lee、Mohamed A. Abdelgawad、Eun Joo Roh、Wagdy M. Eldehna、Claudiu T. Supuran

  DOI：10.1080/14756366.2019.1652282

  日期：2019.1.1

  crucial metalloenzymes that are involved in diverse bioprocesses. We report the synthesis and biological evaluation of novel series of benzenesulfonamides incorporating un/substituted ethyl quinoline-3-carboxylate moieties. The newly synthesised compounds were in vitro evaluated as inhibitors of the cytosolic human (h) isoforms hCA I and II. Both isoforms hCA I and II were inhibited by the quinolines

  抽象的 碳酸酐酶（CAs，EC 4.2.1.1）是涉及多种生物过程的关键金属酶。我们报告了合成和生物学评估的新系列的苯磺酰胺结合未/取代的乙基喹啉-3-羧酸酯部分。新合成的化合物在体外评估为胞质人（h）亚型hCA I和II的抑制剂。此处报道的喹啉在不同程度上均抑制了hCA I和II亚型：h CA I在0.966–9.091μM范围内被K I s抑制，而hCA II在0.083–3.594μM范围内被抑制。主7-氯-6- flouro取代sulphfonamide衍生物6E（ķ我 = 0.083μM）被证明是抑制hCA II活性最强的喹啉，而其次磺酰胺类似物未能抑制hCA II直至10μM，从而证实了主要的磺酰胺类作为锌结合基团的关键作用。 CA抑制活性。
• Synthesis and pharmacological evaluation of pyrazolo[4,3-c]quinolinones as high affinity GABAA-R ligands and potential anxiolytics
  作者：Marisa J. López Rivilli、Anahí V. Turina、Elena A. Bignante、Victor H. Molina、María A. Perillo、Margarita C. Briñon、Elizabeth L. Moyano

  DOI：10.1016/j.bmc.2018.06.021

  日期：2018.8

  aryl-hydrazines affording the final compounds. PQs exhibited different potency in displacing specific [3H]Flunitrazepam binding from the benzodiazepine binding site at the γ-aminobutyric acid receptor (GABAA-R) depending on the substitution of the pyrazoloquinolone nucleus. PCA helped determine how different substituents contributed to the differential behavior of the PQs studied. Compounds with high affinity for

  报道了一系列吡唑并[4,3 - c ]喹啉-3-酮（PQs）的合成，体外配体结合研究和体内高架迷宫测试（EPM）。PQ的多步合成从苯胺和2-（乙氧基亚甲基）丙二酸二乙酯开始，通过Gould-Jacobs反应生成quinolin-4-one核。将这些喹啉酮转化为4-氯喹啉，使其与芳基肼反应，得到最终化合物。PQS在移位特定[表现出各种不同效价3 H]氟硝西泮从苯并二氮杂结合位点在γ氨基丁酸受体结合（GABA甲-R）取决于吡唑并喹诺酮核的取代。PCA有助于确定不同的取代基如何促进所研究的PQ的差异行为。使用高架迷宫（EPM）在Wistar成年雄性大鼠中测试了对GABA A -R具有高亲和力的化合物的抗焦虑特性。因此，在N-1（7b - ii和7c- ii）处带有对甲氧基苯基的PQ在低剂量（0.5-1.0 mg / kg）下显示出显着的抗焦虑活性。同时，PQS设有一个未取代的苯基（7B -我）或p
• Ethene derivatives
  申请人：MAY & BAKER LIMITED

  公开号：EP0174832A2

  公开（公告）日：1986-03-19

  Ethene derivatives of the general formula: wherein R5 represents a heterocyclyl group, containing 1, 2 or 3 rings and one or more heteroatoms selected from nitrogen, oxygen, sulphur and selenium atoms, which is unsubstituted or substituted by one or more substituents R8 [which may be the same or different and each represents a halogen atom or an amino, carboxy, cyano, nitro, hydroxy, oxo, formyl, trifluoromethyl, aryl, aryloxy, arylthio, benzyloxycarbonylamino, sulphamoyl, tetrazol-5-yl, carbamoyl, thiocarbamoyl, arylcarbamoyl or aroyl group, or a straight-or branched-chain alkyl group containing from 1 to 10 carbon atoms, or a straight- or branched-chain alkoxy, alkylthio, alkylsulphinyl, alkylsulphonyl, alkylamino, alkylsulphamoyl, arylalkyl or arylalkoxy group containing from 1 to 10 carbon atoms in the alkyl moiety, a straight- or branched-chain alkanoyl, alkoxycarbonyl, alkoxycarbonylamino, alkylcarbamoyl or alkanoylamino group containing from 2 to 6 carbon atoms, an N-benzyloxycarbonyl-N-alkylamino group wherein the alkylamino moiety is straight- or branched-chain and contains from 1 to 6 carbon atoms, or a dialkylsulphamoyl, dialkylamino or dialkylcarbamoyl group wherein the alkyl moieties may be straight or branched and may each contain from 1 to 6 carbon atoms and may be linked together to form a ring, or a group of the formula -CR4=CR2R3, or an aryl group which is unsubstituted or substituted by one or more substituents RS (as hereinbefore defined), or a heterocyclylalkyl or arylalkyl group wherein the heterocyclyl or aryl moiety is as hereinbefore defined and the alkyl moiety is straight- or branched-chain and contains 1 or 2 carbons atoms, and R1 represents a group of the general formula: wherein R6 represents a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 6 carbon atoms which may be substituted by one or more substituents RS (as hereinbefore defined) or an aryl group which may be substituted by one or more substituents R8 (as hereinbefore defined), or R5 represents a quinonoidal group R7 derived from a nitrogen-containing heterocyclyl group within the definition of R5 as hereinbefore defined, bearing on said ring-nitrogen atom a substituent selected from straight- and branched-chain alkyl groups containing from 1 to 6 carbon atoms which may be substituted by one or more substituents RS (as hereinbefore defined), and aryl groups which may be substituted by one or more substituents RS (as hereinbefore defined), and R1 represents an atom =N-, R4 represents a hydrogen atom or a straight- or branched-chain alkoxy or alkylthio group containing from 1 to 6 carbon atoms, a trifluoromethyl group or a straight- or branched-chain alkyl group containing from 1 to 6 carbon atoms which may be substituted by one or more substituents R8 (as hereinbefore defined), or an aryl group which may be substituted by one or more substituents R8 (as hereinbefore defined), R2 represents a cyano or formyl group, a straight- or branched-chain alkoxycarbonyl or alkylsulphonyl group containing up to 6 carbons, or a dialkylcarbamoyl or dialkylthiocarbamoyl group wherein the alkyl groups may be the same or different and each may be straight or branched and each contains from 1 to 6 carbon atoms, or an aryloxycarbonyl, arylsulphinyl or arylsulphonyl group wherein the aryl moiety may be substituted by one or more substituents R8 (as hereinbefore defined), R3 represents a group within the definition of R2 or a hydrogen atom or a nitro group or an aryl or aroyl group which may be substituted by one or more substituents R8 (as hereinbefore defined) or a straight- or branched-chain alkanoyl group containing up to 6 carbon atoms, and m and n each represents 1 or 2, and pharmaceutically acceptable salts thereof, with the provisos that the following classes of compounds are excluded:- (i) compounds of formula I wherein R5 represents a pyridyl group which is unsubstituted or substituted by one or more substituents R9 which may be the same or different and each represents a group within the definition of Re other than oxo, straight- or branched-chain alkyl containing from 7 to 10 carbon atoms, straight- or branched-chain alkoxy, alkylthio, alkylsulphonyl, alkylamino, alkylsulphamoyl or arylalkyl containing from 7 to 10 carbon atoms in the alkyl moiety, straight- or branched-chain alkylsulphinyl or arylalkoxy containing from 1 to 10 carbon atoms in the alkyl moiety, or a group -CR4=CR2R3 as hereinbefore defined, R2 and R3 may be the same or different and each represents a phenylsulphonyl group which may be unsubstituted or substituted by one or more substituents R9 (as hereinbefore defined), R' represents a group of formula II, R4 and R6 represent hydrogen atoms and m and n both represent 1; (ii) compounds of formula I wherein R5 represents a 5-halogenopyrid-2-yl group, R2 and R3 both represent cyano groups, R1 represents a group of formula II, R4 and R° represent hydrogen atoms and m and n both represent 1; and (iii) compounds of formula I wherein R5 represents a 1,2,4-triazolo[4,8-a]-quinoline group which is unsubstituted or substituted by one or more substituents R10 which may be the same or different and each represents a group within the definition of R9 or a straight- or branched-chain alkylsulphinyl group containing from 1 to 6 carbon atoms, R2 and R3 may be the same or different and each represents a cyano group, a straight- or branched-chain alkoxycarbonyl group containing from 2 to 6 carbon atoms, or a phenylsulphonyl group which may be unsubstituted or substituted by one or more substituents R10 (as hereinbefore defined), R' represents a group of formula II, R4 and R6 represent hydrogen atoms and m and n both represent 1, possess useful pharmacological properties.

  以下是对文本的中文翻译： **丙烯衍生物的通式**： 其中，R5代表一个杂环基，包含1、2或3个环，并且含有1个或多个选自氮、氧、硫和硒原子的杂原子，该杂环基可以是未取代的，或被一个或多个R8取代基取代（R8可以相同或不同，每个R8代表一个卤素原子；或者一个氨基、羧基、氰基、硝基、羟基、羰基、甲酰基、三氟甲基、芳基、芳氧基、芳硫基、苄氧羰基氨基、硫脲基、5-四唑基、羰基氨基、硫代羰基氨基、芳基羰基氨基或芳酰基；或者一个直链或支链烷基，含有1至10个碳原子；或者一个直链或支链烷氧基、烷硫基、烷亚砜基、烷砜基、烷氨基、烷硫脲基、芳基烷基或芳基烷氧基，其中烷基部分含有1至10个碳原子；或者一个直链或支链烷酰基、烷氧基羰基、烷氧基羰基氨基、烷基羰基氨基或烷酰基氨基，含有2至6个碳原子；或者一个N-苄氧羰基-N-烷基氨基，其中烷基氨基部分为直链或支链，含有1至6个碳原子；或者一个二烷基硫脲基、二烷基氨基或二烷基羰基氨基，其中烷基部分可以为直链或支链，每个烷基部分含有1至6个碳原子，且烷基部分可以彼此连接形成一个环；或者一个通式为-CR4=CR2R3的基团；或者一个未取代的芳基，或被一个或多个R8取代基取代的芳基；或者一个杂环基烷基或芳基烷基，其中杂环基或芳基部分如前所定义，烷基部分为直链或支链，含有1或2个碳原子）。 R1代表一个通式为的基团： 其中，R6代表一个氢原子；或一个直链或支链烷基，含有1至6个碳原子，该烷基可以被一个或多个R8取代基取代（如前所定义）；或一个芳基，可以被一个或多个R8取代基取代（如前所定义）。 此外，R5还可以代表一个由含氮杂环基衍生而来的醌状基团R7，该杂环基如前所定义的R5，其中环氮原子上取代有一个选自以下的基团：直链或支链烷基，含有1至6个碳原子，该烷基可以被一个或多个R8取代基取代（如前所定义）；或一个芳基，可以被一个或多个R8取代基取代（如前所定义）。 R1代表一个=NH原子；R4代表一个氢原子，或一个直链或支链烷氧基、烷硫基，含有1至6个碳原子；或一个三氟甲基基团；或一个直链或支链烷基，含有1至6个碳原子，该烷基可以被一个或多个R8取代基取代（如前所定义）；或一个芳基，可以被一个或多个R8取代基取代（如前所定义）。 R2代表一个氰基或甲酰基；或一个直链或支链烷氧基羰基或烷硫基，含有不超过6个碳原子；或一个二烷基羰基氨基或二烷基硫代羰基氨基，其中两个烷基可以相同或不同，每个烷基为直链或支链，含有1至6个碳原子；或一个芳氧基羰基、芳硫基或芳硫基羰基，其中芳基部分可以被一个或多个R8取代基取代（如前所定义）。 R3代表一个与R2定义范围内的基团，或一个氢原子；或一个硝基；或一个芳基；或一个芳酰基，可以被一个或多个R8取代基取代（如前所定义）；或一个直链或支链烷酰基，含有不超过6个碳原子。 m和n各自代表1或2。 除以下化合物类别外，上述结构及其药学上可接受的盐类具有有用的药理学性质： (i) 通式为I的化合物，其中R5代表一个吡啶基，该吡啶基可以是未取代的，或被一个或多个R9取代基取代，R9可以相同或不同，每个R9代表一个基团，其定义范围包括：R8（但不包括氧代基、直链或支链烷基，含有7至10个碳原子；直链或支链烷氧基、烷硫基、烷硫基、烷氨基、烷硫脲基、或芳基烷基，其中烷基部分含有7至10个碳原子；直链或支链烷亚砜基，或芳基烷氧基，其中烷基部分含有1至10个碳原子）；或一个如前所定义的-CR4=CR2R3基团。其中，R2和R3可以相同或不同，各自代表一个苯硫基，可以是未取代的，或被一个或多个R9取代基取代（如前所定义）。R’代表一个通式II的基团。R4和R6代表氢原子，m和n均为1。 (ii) 通式为I的化合物，其中R5代表一个5-卤素取代吡啶-2-基，R2和R3均为氰基，R1代表一个通式II的基团，R4和R°代表氢原子，m和n均为1。 (iii) 通式为I的化合物，其中R5代表一个1,2,4-三唑[4,8-a]-喹啉基，该基团可以是未取代的，或被一个或多个R10取代基取代，R10可以相同或不同，每个R10代表一个基团，其定义范围包括：R9（如前所定义），或一个直链或支链烷亚砜基，含有1至6个碳原子。R2和R3可以相同或不同，各自代表一个氰基、一个直链或支链烷氧基羰基（含有2至6个碳原子），或一个苯硫基，可以是未取代的，或被一个或多个R10取代基取代（如前所定义）。R’代表一个通式II的基团。R4和R6代表氢原子，m和n均为1。 上述化合物在排除了特定结构后，具有有用的药理学性质。
• Evaluation of 3-Carboxy-4(1<i>H</i>)-quinolones as Inhibitors of Human Protein Kinase CK2
  作者：Andriy G. Golub、Olexander Ya. Yakovenko、Volodymyr G. Bdzhola、Vladislav M. Sapelkin、Piotr Zien、Sergiy M. Yarmoluk

  DOI：10.1021/jm050048t

  日期：2006.11.1

  Due to the emerging role of protein kinase CK2 as a molecule that participates not only in the development of some cancers but also in viral infections and inflammatory failures, small organic inhibitors of CK2, besides application in scientific research, may have therapeutic significance. In this paper, we present a new class of CK2 inhibitorss3-carboxy-4(1H)-quinolones. This class of inhibitors has been selected via receptor-based virtual screening of the Otava compound library. It was revealed that the most active compounds, 5,6,8-trichloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (7) (IC50 = 0.3 mu M) and 4-oxo-1,4-dihydrobenzo[h] quinoline-3-carboxylic acid (9) (IC50 = 1 AM), are ATP competitive (K-i values are 0.06 and 0.28 mu M, respectively). Evaluation of the inhibitors on seven protein kinases shows considerable selectivity toward CK2. According to theoretical calculations and experimental data, a structural model describing the key features of 3-carboxy-4(1H)-quinolones responsible for tight binding to CK2 active site has been developed.